New patterns of relapse in multiple myeloma: a case of "light chain escape" in which FLC predicted relapse earlier than urine and serum immunofixation.

Clin Chem Lab Med 2016 Jun;54(6):991-5

Multiple myeloma (MM) is characterized, in about 80% of cases, by the production of monoclonal intact immunoglobulin and more than 95% of them have elevated concentrations of involved (i.e. of the same class of intact immunoglobulin) free light chain (FLC). The introduction of novel therapeutic strategies has changed the natural history of the disease, leading to new manifestations of relapse. Light chain escape (LCE) is a pattern of relapse in which the FLC increase is not accompanied by a concomitant raise of the original monoclonal component (MC). Here we present a case of a 55-year-old man with an IgG kappa MM stage III diagnosed in September 2007. At presentation an IgG kappa MC and urine Bence Jones protein (BJP) kappa were present. Bone marrow biopsy (BMB) showed the presence of 80% monotypic kappa plasma cells (PCs). The patient received bortezomib, thalidomide, dexamethasone before undergoing a double autologous stem cell transplantation (ASCT) in October 2008 and April 2009. In May 2011 he relapsed showing the same pattern of presentation and treatment with lenalidomide and dexamethasone was started. ln May 2013 serum and urine immunofixation and FLC became negative. In September 2014, an increase of kappa FLC was observed, while serum and urine immunofixations remained negative until January 2015, when urine immunofixation became positive. Eventually, in February 2015, serum immunofixation revealed the presence of a free kappa MC. After a new BMB showing 80% of monotypic kappa PCs, a LCE relapse was diagnosed and the patient started the treatment with bendamustine, bortezomib and dexamethasone. In the present case, the increase of kappa FLC has indicated relapse 4 and 5 months earlier than urine and serum IFE, respectively. Our observation confirms that it is advisable to routinely perform FLC or BJP during follow up of MM patients undergoing ASCT and/or treatment with biological drugs to ensure that LCE is not missed.

Download full-text PDF

Source
http://dx.doi.org/10.1515/cclm-2015-0689DOI Listing
June 2016

Publication Analysis

Top Keywords

light chain
8
kappa
8
intact immunoglobulin
8
serum immunofixation
8
urine serum
8
igg kappa
8
monotypic kappa
8
kappa flc
8
increase kappa
8
urine immunofixation
8
serum urine
8
earlier urine
8
80% monotypic
8
multiple myeloma
8
flc
7
urine
6
relapse
5
serum
5
relapsed showing
4
showing pattern
4

Similar Publications

Comparison of serum free light chain and urine electrophoresis for the detection of the light chain component of monoclonal immunoglobulins in light chain and intact immunoglobulin multiple myeloma.

Haematologica 2016 Mar 3;101(3):356-62. Epub 2015 Dec 3.

Institut Universitaire du Cancer, University Hospital, CRCT, INSERM U1037, Toulouse, France

Response criteria for multiple myeloma are based upon changes in monoclonal protein levels quantified using serum and/or urine protein electrophoresis. The latter lacks sensitivity at low monoclonal protein levels and since 2001, the serum free light chain test has been available and its clinical utility proven, yet guidelines have not recommended it as a replacement for urine assessment. Herein we evaluated responses using serum free light chain measurements and serum and urine electrophoresis after 2 and 4 cycles of therapy and after stem cell transplantation in 25 light chain and 157 intact immunoglobulin myeloma patients enrolled in the IFM 2007-02 MM trial. Read More

View Article and Full-Text PDF
March 2016

Assessing the efficiency of free light chain assay in monitoring patients with multiple myeloma before and after autologous stem cell transplantation along with serum protein electrophoresis and serum protein immunofixation.

Roum Arch Microbiol Immunol 2011 Jan-Mar;70(1):15-22

Fundeni Clinical Institute, Bucharest, Romania.

Monoclonal gammopathies are a group of disorders, referred to as paraproteinaemias, dysproteinaemias or immunoglobulinopathies, associated with monoclonal proliferation of plasma cells. Monoclonal immunoglobulin secreted by these cells is an indicator of clonal proliferation. The aim of this study is to analyze the efficiency of three methods: serum protein electrophoresis (SPE), serum protein immunofixation (IFE) and FLC (free light chain) assay for the diagnosis and monitoring of the tumor burden in multiple myeloma. Read More

View Article and Full-Text PDF
July 2011

Polyclonal free light chain of Ig may interfere with interpretation of monoclonal free light chain κ/λ ratio.

Ann Clin Lab Sci 2010 ;40(4):348-53

Department of Pathology and Laboratory Medicine, University of Louisville, KY, USA.

There is controversy about whether a sensitive assay for the serum Ig free light chain (FLC) κ/λ ratio can replace urine immunofixation electrophoresis (UIFE). This report describes two untreated patients in whom monoclonal FLCs were identified in urine despite normal serum FLC κ/λ ratios. Unlike the classical serum electrophoretic patterns in multiple myeloma, both serum samples showed adequate amounts of polyclonal Ig. Read More

View Article and Full-Text PDF
February 2011

Development of a highly-sensitive multi-plex assay using monoclonal antibodies for the simultaneous measurement of kappa and lambda immunoglobulin free light chains in serum and urine.

J Immunol Methods 2013 May 4;391(1-2):1-13. Epub 2013 Feb 4.

Clinical Immunology Service, School of Immunity and Infection, College of Medical and Dental Sciences, University of Birmingham, Birmingham, United Kingdom.

Monoclonal κ and λ immunoglobulin free light chain (FLC) paraproteins in serum and urine are important markers in the diagnosis and monitoring of B cell dyscrasias. Current nephelometric and turbidimetric methods that use sheep polyclonal antisera to quantify serum FLC have a number of well-observed limitations. In this report, we describe an improved method using specific mouse anti-human FLC monoclonal antibodies (mAbs). Read More

View Article and Full-Text PDF
May 2013